99mTc-MIRC208 SPECT/CT Imaging for HER2-Positive Cancer Patients
NCT04591652
·
clinicaltrials.gov ↗
NA
Phase
UNKNOWN
Status
200
Enrollment
OTHER
Sponsor class
Conditions
Cancer
Interventions
DRUG:
99mTc-MIRC208
Sponsor
Peking University Cancer Hospital & Institute